A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer

doi:10.1016/j.canlet.2017.04.023

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 化妝品應用與管理系(所) > 期刊論文 > Item 310902800/31611

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31611

標題:	A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer
作者:	Wu, Yuan-Hua Hong, Chi-Wei Wang, Yi-Ching Huang, Wei-Jan Yeh, Ya-Ling Wang, Bour-Jr Wang, Ying-Jan Chiu, Hui-Wen
貢獻者:	Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth Natl Cheng Kung Univ, Coll Med,Natl Cheng Kung Univ Hosp, Dept Radiat Oncol Natl Cheng Kung Univ, Dept Pharmacol Natl Cheng Kung Univ, Inst Basic Med Sci Taipei Med Univ, Grad Inst Pharmacognosy Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Chia Nan Univ Pharm & Sci, Inst Cosmet Sci Asia Univ, Dept Biomed Informat China Med Univ,China Med Univ Hosp, Dept Med Res Taipei Med Univ, Coll Med, Grad Inst Clin Med Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med
關鍵字:	DNA damage DNA repair Ubiquitin-proteasome system Triple-negative breast cancer
日期:	2017-08-01
上傳時間:	2018-11-30 15:50:09 (UTC+8)
出版者:	Elsevier Ireland Ltd
摘要:	Triple-negative breast cancer (TNBC) treatment offers only limited benefits, and it is very relevant given the significant number of deaths that it causes. DNA repair pathways can enable tumor cells to survive DNA damage that is induced by chemotherapeutic or radiation treatments. Histone deacetylase inhibitors (HDACi) inhibited DNA repair proteins. However, the detailed mechanisms for this inhibition remain unclear. In the present study, we investigated whether a newly developed HDACi, TMU-35435, could enhance etoposide cytotoxicity by inhibiting DNA repair proteins in triple-negative breast cancer. We found synergistic cytotoxicity following treatment of 4T1 cells with etoposide and TMU-35435. Furthermore, TMU-35435 enhances etoposide-induced DNA damage by inhibiting the DNA repair pathway (non-homologous end joining, NHEJ). TMU-35435 suppresses the NHEJ pathway through the ubiquitination of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition, TMU-35435 ubiquitinated DNA-PKcs by inducing the interaction between RNF144A (an E3 ligase) and DNA-PKcs. The combined treatment induced apoptosis and autophagic cell death in 4T1 cells. In an orthotopic breast cancer model, combined treatment with TMU-35435 and etoposide showed anti-tumor growth through the increase of DNA damage and cell death. Taken together, our data suggest that TMU-35435 enhances etoposide cytotoxicity by regulating ubiquitin-proteasome system and inhibiting the DNA repair pathway in TNBC. (C) 2017 Elsevier B.V. All rights reserved.
關聯:	Cancer Letters, v.400, pp.79-88
显示于类别:	[化妝品應用與管理系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	1382	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....